What Safeguards Do Telehealth Ketamine Programs Use to Prevent Misuse?

What safeguards do telehealth ketamine programs use to prevent misuse? Legitimate programs layer several controls on top of each other: intake screening for substance use history, checks of the state Prescription Drug Monitoring Program (PDMP), limited medication quantities tied to a defined number of sessions, structured dosing schedules, required session sitters, regular clinical check-ins, pharmacy-level tracking, and discharge protocols for confirmed misuse.

Ketamine is a Schedule III controlled substance under the federal Controlled Substances Act, a category reserved for drugs with accepted medical uses alongside documented potential for misuse and moderate physical dependence, according to the DEA. When a patient receives ketamine at home through telehealth rather than under direct clinic supervision, that classification raises a fair question: what actually stops a patient from taking more than prescribed, using it outside of sessions, or sharing it with someone else? The DEA, state medical boards, and the clinical community all treat this as a real operational risk that at-home programs are expected to manage, not a hypothetical concern. This guide walks through the safeguards responsible telehealth ketamine providers use at each stage of care, along with the honest limitations of those safeguards.

Substance Use and Psychological Screening

Screening starts before a single dose is prescribed. During intake, a trained clinician reviews current substance use, including alcohol, cannabis, and other controlled substances, any history of substance use disorder, prior recreational or therapeutic ketamine use, family history of substance use disorders, and current or past addiction treatment. Patients with an active substance use disorder, particularly involving dissociative drugs, opioids, or alcohol, may be excluded from at-home ketamine programs or asked to show a period of stability in addiction treatment first.

Clinicians also assess psychological risk factors that do not show up on a substance use questionnaire: whether the patient is seeking symptom relief for a diagnosed condition versus primarily interested in the dissociative effect, whether they understand ketamine as a medical treatment rather than a recreational one, how they typically cope with distress, and whether they have a stable living situation and support system. This screening is imperfect. A patient determined to misuse ketamine can minimize or conceal relevant history. But a thorough evaluation meaningfully narrows the pool of high-risk applicants.

Prescription Drug Monitoring Program (PDMP) Checks

A Prescription Drug Monitoring Program (PDMP) is a state-run electronic database that logs controlled substance prescriptions dispensed to a patient, so prescribers can see what else that patient has been prescribed and by whom. Checking the PDMP lets a telehealth ketamine provider see whether a patient is already receiving ketamine from another provider, whether they are on other controlled substances that raise misuse risk or create dangerous interactions, and whether refill patterns across providers look unusual. Most states legally require a PDMP check before prescribing a controlled substance. A provider that skips this step is failing a basic regulatory and clinical obligation, not just a best practice. Requirements and enforcement vary by state; see our state ketamine regulations guide and telehealth legality overview for more on how oversight differs across the country.

Limited Quantities and Structured Dosing

Responsible programs prescribe a defined number of sessions per shipment, often four to six, rather than a large open-ended supply, and require a clinical check-in before authorizing a refill. Patients are given a specific dose for a specific session schedule, such as one troche per session once a week, rather than a supply they can use at their own discretion. That structure makes deviations detectable: running out early, requesting extra medication, or asking to increase the dose all become visible signals rather than invisible drift. It also reinforces, procedurally, that ketamine is a supervised medical treatment rather than a self-directed one. For context on how quantity and refill structures typically work, see our comparison of monthly subscription versus per-session models.

Some providers also ask patients to log each session, including the dose taken and their experience. Discrepancies between what was prescribed and what session logs or refill timing suggest was actually used can flag off-protocol use, though this tracking still depends partly on patient self-reporting.

Pharmacy-Level Controls

The licensed compounding pharmacies that prepare and ship ketamine for telehealth programs run their own checks: verifying the prescriber's DEA registration before dispensing, reporting every ketamine prescription to the state PDMP, tracking delivery to confirm the medication reaches the intended patient, and in some cases requiring a signature on delivery. Medication ships in packaging labeled with the contents, dose, patient, and prescriber, and some pharmacies use packaging designed to show evidence of tampering, adding a further layer of accountability between pharmacy and patient.

Clinical Check-Ins and Session Sitters

Ongoing clinical contact does double duty as therapy and as misuse prevention. During follow-up visits, clinicians track the patient's response using standardized measures such as the PHQ-9 for depression or the GAD-7 for anxiety, and ask questions designed to reveal whether the medication is being used as prescribed. Clinicians trained in addiction medicine watch for behavioral markers of developing dependence: preoccupation with the medication, anxiety about running out, using ketamine to manage acute emotional crises instead of following the prescribed protocol, and resistance to dose reduction.

Most telehealth ketamine programs also require a sober adult to be present during sessions. This session sitter serves both as a safety measure for medical emergencies and as a behavioral check. Some programs ask sitters to confirm the session occurred as the patient described it, and a sitter who notices the patient taking more than prescribed, dosing at unscheduled times, or showing signs of intoxication outside of sessions can flag it to the clinical team.

Behavioral Signals

Programs also watch for patterns across refill requests, dose increase requests without clinical improvement, urgent messaging about medication access, missed follow-up appointments paired with continued medication requests, and continued requests for ketamine despite no measured improvement in symptoms. No single signal confirms misuse, but a pattern of several triggers clinical review.

Treatment Agreements and Discharge Protocols

Many programs require patients to sign a controlled substance treatment agreement stating that they will use ketamine only as prescribed, will not share or sell it, will store it securely, will attend required follow-ups, and consent to PDMP checks, with discharge from the program as a stated consequence of violating those terms. The agreement does not physically stop misuse, but it sets clear expectations and gives the program a documented basis for ending treatment if misuse is confirmed.

When misuse is suspected, responsible programs follow a defined process: a clinical conversation about the concerning behavior, an assessment of whether it reflects misuse, protocol confusion, or something else, increased monitoring if the picture is unclear, treatment modification such as a dose reduction or an added sitter requirement, and discharge with a referral to substance use treatment resources if misuse is confirmed. Programs also carry a PDMP notation and, where required, a regulatory reporting obligation once misuse is confirmed. Discharge is meant to redirect the patient to appropriate care, not to punish them, but a program that keeps prescribing to a patient it knows is misusing the medication is failing both its clinical and legal obligations. Diversion of controlled substances is a documented federal enforcement priority; see our coverage of a federal investigation into online ketamine sellers for an example of how regulators respond when at-home safeguards fail. Records of these reviews are also handled under HIPAA; see our guide to privacy and HIPAA in telehealth ketamine care for more on how patient records are managed.

Programs also run internal population-level reviews, checking whether particular prescribers approve unusually more patients than others, whether refill rates are climbing across the patient base, whether adverse event reports are increasing, or whether patients are dropping out of monitoring components while still receiving medication. These reviews help a program catch weaknesses in its own safeguards rather than relying only on individual case review.

Sources: DEA, Ketamine Drug Fact Sheet, federal scheduling and diversion information; National Institute on Drug Abuse, Ketamine DrugFacts, pharmacology and misuse potential; Schak KM, et al. (2016), "Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment," American Journal of Psychiatry, 173(3), 215-218; Liu Y, et al. (2016), "Ketamine Abuse Potential and Use Disorder," Brain Research Bulletin, 126(Pt 1), 68-73; Short B, et al. (2018), "Side-Effects Associated with Ketamine Use in Depression: A Systematic Review," Lancet Psychiatry, 5(1), 65-78.